Performance of Xylazine Qualitative Immunoassays Designed for Drug Checking in Urine Samples
Year: 2025
Type: article
Language: en
Topic: Veterinary Pharmacology and Anesthesia
Authors and affiliations:
raw_author_name: Emma Pattillo
raw_affiliation_strings: Analyses were supported by NIH R01DA052937 (KED), UG3DA048734 (ASH and KED), and R01DA054101 (CLB)
CLB received funding from the National Institute on Drug Abuse, Cure Addiction Now, Canopy Growth Corporation, and Pear Therapeutics through her university to conduct research and has consulted for Mind Med, Inc. ASH has consulted for Gilgamesh Pharmaceuticals, receives study medication and logistical support from Merck Inc. for a clinical trial (not associated with this manuscript), and received research funding from Ashley Addiction Treatment and Indivior Inc. through his university. KED has served on a study steering committee for Indivior Inc. and receives funding through her institution from the National Institute on Drug Abuse and Cure Addiction Now. The remaining authors report no conflicts of interest
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (YX, AM, DS, MB, NB, JDE, CLB, ASH)
Department of Psychiatry, Kahlert Institute for Addiction Medicine, University of Maryland, Baltimore, MD (EP, KED)
raw_author_name: Yi Xie
raw_affiliation_strings: Analyses were supported by NIH R01DA052937 (KED), UG3DA048734 (ASH and KED), and R01DA054101 (CLB)
CLB received funding from the National Institute on Drug Abuse, Cure Addiction Now, Canopy Growth Corporation, and Pear Therapeutics through her university to conduct research and has consulted for Mind Med, Inc. ASH has consulted for Gilgamesh Pharmaceuticals, receives study medication and logistical support from Merck Inc. for a clinical trial (not associated with this manuscript), and received research funding from Ashley Addiction Treatment and Indivior Inc. through his university. KED has served on a study steering committee for Indivior Inc. and receives funding through her institution from the National Institute on Drug Abuse and Cure Addiction Now. The remaining authors report no conflicts of interest
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (YX, AM, DS, MB, NB, JDE, CLB, ASH)
Department of Psychiatry, Kahlert Institute for Addiction Medicine, University of Maryland, Baltimore, MD (EP, KED)
raw_author_name: Aicha Monteiro
raw_affiliation_strings: Analyses were supported by NIH R01DA052937 (KED), UG3DA048734 (ASH and KED), and R01DA054101 (CLB)
CLB received funding from the National Institute on Drug Abuse, Cure Addiction Now, Canopy Growth Corporation, and Pear Therapeutics through her university to conduct research and has consulted for Mind Med, Inc. ASH has consulted for Gilgamesh Pharmaceuticals, receives study medication and logistical support from Merck Inc. for a clinical trial (not associated with this manuscript), and received research funding from Ashley Addiction Treatment and Indivior Inc. through his university. KED has served on a study steering committee for Indivior Inc. and receives funding through her institution from the National Institute on Drug Abuse and Cure Addiction Now. The remaining authors report no conflicts of interest
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (YX, AM, DS, MB, NB, JDE, CLB, ASH)
Department of Psychiatry, Kahlert Institute for Addiction Medicine, University of Maryland, Baltimore, MD (EP, KED)
raw_author_name: Dhathri Srungaram
raw_affiliation_strings: Analyses were supported by NIH R01DA052937 (KED), UG3DA048734 (ASH and KED), and R01DA054101 (CLB)
CLB received funding from the National Institute on Drug Abuse, Cure Addiction Now, Canopy Growth Corporation, and Pear Therapeutics through her university to conduct research and has consulted for Mind Med, Inc. ASH has consulted for Gilgamesh Pharmaceuticals, receives study medication and logistical support from Merck Inc. for a clinical trial (not associated with this manuscript), and received research funding from Ashley Addiction Treatment and Indivior Inc. through his university. KED has served on a study steering committee for Indivior Inc. and receives funding through her institution from the National Institute on Drug Abuse and Cure Addiction Now. The remaining authors report no conflicts of interest
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (YX, AM, DS, MB, NB, JDE, CLB, ASH)
Department of Psychiatry, Kahlert Institute for Addiction Medicine, University of Maryland, Baltimore, MD (EP, KED)
raw_author_name: Melanie Baime
raw_affiliation_strings: Analyses were supported by NIH R01DA052937 (KED), UG3DA048734 (ASH and KED), and R01DA054101 (CLB)
CLB received funding from the National Institute on Drug Abuse, Cure Addiction Now, Canopy Growth Corporation, and Pear Therapeutics through her university to conduct research and has consulted for Mind Med, Inc. ASH has consulted for Gilgamesh Pharmaceuticals, receives study medication and logistical support from Merck Inc. for a clinical trial (not associated with this manuscript), and received research funding from Ashley Addiction Treatment and Indivior Inc. through his university. KED has served on a study steering committee for Indivior Inc. and receives funding through her institution from the National Institute on Drug Abuse and Cure Addiction Now. The remaining authors report no conflicts of interest
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (YX, AM, DS, MB, NB, JDE, CLB, ASH)
Department of Psychiatry, Kahlert Institute for Addiction Medicine, University of Maryland, Baltimore, MD (EP, KED)
raw_author_name: Nicole Brown
raw_affiliation_strings: Analyses were supported by NIH R01DA052937 (KED), UG3DA048734 (ASH and KED), and R01DA054101 (CLB)
CLB received funding from the National Institute on Drug Abuse, Cure Addiction Now, Canopy Growth Corporation, and Pear Therapeutics through her university to conduct research and has consulted for Mind Med, Inc. ASH has consulted for Gilgamesh Pharmaceuticals, receives study medication and logistical support from Merck Inc. for a clinical trial (not associated with this manuscript), and received research funding from Ashley Addiction Treatment and Indivior Inc. through his university. KED has served on a study steering committee for Indivior Inc. and receives funding through her institution from the National Institute on Drug Abuse and Cure Addiction Now. The remaining authors report no conflicts of interest
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (YX, AM, DS, MB, NB, JDE, CLB, ASH)
Department of Psychiatry, Kahlert Institute for Addiction Medicine, University of Maryland, Baltimore, MD (EP, KED)
raw_author_name: Jennifer D. Ellis
raw_affiliation_strings: Analyses were supported by NIH R01DA052937 (KED), UG3DA048734 (ASH and KED), and R01DA054101 (CLB)
CLB received funding from the National Institute on Drug Abuse, Cure Addiction Now, Canopy Growth Corporation, and Pear Therapeutics through her university to conduct research and has consulted for Mind Med, Inc. ASH has consulted for Gilgamesh Pharmaceuticals, receives study medication and logistical support from Merck Inc. for a clinical trial (not associated with this manuscript), and received research funding from Ashley Addiction Treatment and Indivior Inc. through his university. KED has served on a study steering committee for Indivior Inc. and receives funding through her institution from the National Institute on Drug Abuse and Cure Addiction Now. The remaining authors report no conflicts of interest
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (YX, AM, DS, MB, NB, JDE, CLB, ASH)
Department of Psychiatry, Kahlert Institute for Addiction Medicine, University of Maryland, Baltimore, MD (EP, KED)
raw_author_name: Cecilia L. Bergeria
raw_affiliation_strings: Analyses were supported by NIH R01DA052937 (KED), UG3DA048734 (ASH and KED), and R01DA054101 (CLB)
CLB received funding from the National Institute on Drug Abuse, Cure Addiction Now, Canopy Growth Corporation, and Pear Therapeutics through her university to conduct research and has consulted for Mind Med, Inc. ASH has consulted for Gilgamesh Pharmaceuticals, receives study medication and logistical support from Merck Inc. for a clinical trial (not associated with this manuscript), and received research funding from Ashley Addiction Treatment and Indivior Inc. through his university. KED has served on a study steering committee for Indivior Inc. and receives funding through her institution from the National Institute on Drug Abuse and Cure Addiction Now. The remaining authors report no conflicts of interest
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (YX, AM, DS, MB, NB, JDE, CLB, ASH)
Department of Psychiatry, Kahlert Institute for Addiction Medicine, University of Maryland, Baltimore, MD (EP, KED)
raw_author_name: Andrew S. Huhn
raw_affiliation_strings: Analyses were supported by NIH R01DA052937 (KED), UG3DA048734 (ASH and KED), and R01DA054101 (CLB)
CLB received funding from the National Institute on Drug Abuse, Cure Addiction Now, Canopy Growth Corporation, and Pear Therapeutics through her university to conduct research and has consulted for Mind Med, Inc. ASH has consulted for Gilgamesh Pharmaceuticals, receives study medication and logistical support from Merck Inc. for a clinical trial (not associated with this manuscript), and received research funding from Ashley Addiction Treatment and Indivior Inc. through his university. KED has served on a study steering committee for Indivior Inc. and receives funding through her institution from the National Institute on Drug Abuse and Cure Addiction Now. The remaining authors report no conflicts of interest
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (YX, AM, DS, MB, NB, JDE, CLB, ASH)
Department of Psychiatry, Kahlert Institute for Addiction Medicine, University of Maryland, Baltimore, MD (EP, KED)
raw_author_name: Kelly E. Dunn
raw_affiliation_strings: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (YX, AM, DS, MB, NB, JDE, CLB, ASH)
reprint requests to Kelly E. Dunn, PhD, MBA, Kahlert Institute for Addiction Medicine, University of Maryland, Baltimore, 725 W Lombard Street, Baltimore, MD 21201. E-mail: [email protected]
CLB received funding from the National Institute on Drug Abuse, Cure Addiction Now, Canopy Growth Corporation, and Pear Therapeutics through her university to conduct research and has consulted for Mind Med, Inc. ASH has consulted for Gilgamesh Pharmaceuticals, receives study medication and logistical support from Merck Inc. for a clinical trial (not associated with this manuscript), and received research funding from Ashley Addiction Treatment and Indivior Inc. through his university. KED has served on a study steering committee for Indivior Inc. and receives funding through her institution from the National Institute on Drug Abuse and Cure Addiction Now. The remaining authors report no conflicts of interest